Business Wire

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 ...
Pharmabiz

Bristol Myers announces positive results from POETYK PSO-1 phase 3 study of deucravacitinib ...

Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...